ENZYMES INHIBITION Russian patent published in 2017 - IPC C07D471/04 A61K31/4196 A61K31/437 A61P11/00 

FIELD: pharmacology.

SUBSTANCE: invention relates to the compound of the formula or its pharmaceutically acceptable salt. In the formula (I) R₁ represents -CN; R₂ is selected from (C₁-C₄)haloalkyl, (C₁-C₄)haloalkoxy; W represents the (i) 5-membered heteroaryl ring, where two or three ring-atoms represent the hetero-atom N, optionally substituted by one group, which is selected from the (C₁-C₄) alkyl, the group -NHR₁₈, and from the group -COOR₂₈; or (iii) phenyl group; R₃ represents the group -CH₂-R₂₃; R₅ represents the hydrogen; R₆ represents the hydrogen; A₁ represents the group -CR₇=; A₂ represents the group =CR₈- or the group =N-; A₃--A₄ represents the group, which is selected from the group -CR₄=N-, the group -CR₄=CR₉- and the group NR₁₇-CO-; R₄ represents the group, which is selected from the hydrogen, the (C₁-C₄) alkyl, -NR₁₀R₁₁, -NHCOR₁₂, -NHCOO-R₁₃, -NHCONR₂₇-R₁₄, the (C₁-C₄)alkoxy, -NH(CH₂)_n-SO₂(C₁-C₄)alkyl, -(NH)_q(CH₂)_n-(C₆H₄)-SO₂(C₁-C₄)alkyl, -NHSO₂(C₁-C₄) alkyl and -(NH)_r(CH₂)_nCONR₁₅R₁₆; the other chemical groups value is indicated in the invention formula. The invention also relates to the pharmaceutical composition and to the method of the disease or state treatment, where HNE is implicated.

EFFECT: there are new compounds of the formula that offer the inhibitors' properties of the human neutrophil elastase.

14 cl, 97 ex